E3A Healthcare is a global women’s health technology company founded in 2019 and spun out of the National University of Singapore. We build AI-driven, non-invasive medical devices that move critical care from the hospital into the home, starting with pregnancy, newborn care, and women’s chronic conditions.  Our platform includes Modoo™, an AI-powered passive fetal monitoring and labor prediction system; Bilimonitor™, a scalable home-based neonatal jaundice monitoring and phototherapy solution; and Nora™, a first-in-class, non-drug neuromodulation therapy for endometriosis and adenomyosis. Together, these products form a data-driven care platform with strong unit economics, recurring revenue, and clear regulatory pathways.  E3A has demonstrated meaningful commercial traction, having already served over 500,000 families across Asia through hospital partnerships and direct-to-consumer channels, with usage and revenue growing rapidly year over year. With ISO 13485-certified manufacturing, 130+ global patents, and regulatory approvals in Asia alongside FDA and EU pathways in progress, E3A Healthcare is scaling globally to build the foundational infrastructure for the next generation of women’s health care.